IP Library Assignment 073032/0390
Patent Assignment
Reel/Frame 073032/0390

Change of Address

Recorded: 2025-10-08 Pages: 7
Assignor
Assignee
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
GSK MEDICINES RESEARCH CENTRE, GUNNELS WOOD ROAD, STEVENAGE, SG1 2NY, UNITED KINGDOM
Covered Properties (158)
Heterocyclic Amides Useful as Protein Modulators
Application: 17/156,893 →
Publication: US 2021/0139473
Nozzle for a Nasal Inhaler
Patent: 8,656,909 →
Application: 13/167,200 →
Publication: US 2011/0253752
Heterocyclic Amides as Kinase Inhibitors
Application: 16/408,718 →
Publication: US 2019/0262356
Sanfetrinem or a Salt or Ester Thereof for Use in Treating Mycobacterial Infection
Application: 16/611,908 →
Publication: US 2020/0289462
Icos Binding Proteins
Application: 16/441,474 →
Publication: US 2020/0123257
Compounds
Application: 16/524,238 →
Publication: US 2020/0055863
Heterocyclic Amides Useful as Protein Modulators
Application: 16/091,189 →
Substituted Pyridines as Inhibitors of DNMT1
Application: 16/309,121 →
Publication: US 2019/0194166
Actuation Counter
Patent: 8,656,911 →
Application: 12/867,897 →
Publication: US 2010/0313884
Novel Processes for the Production of Oligonucleotides
Application: 15/643,535 →
Publication: US 2018/0023122
Icos Binding Proteins
Application: 15/246,662 →
Publication: US 2016/0362494
Compounds
Patent: 9,783,546 →
Application: 15/327,685 →
Publication: US 2017/0204108
Icos Binding Proteins
Patent: 9,738,718 →
Application: 15/387,161 →
Publication: US 2017/0174767
Buffer System for Protein Purification
Patent: 9,868,761 →
Application: 15/450,106 →
Publication: US 2017/0174721
Heterocyclic Amides as Kinase Inhibitors
Application: 15/459,141 →
Publication: US 2017/0183332
Novel Soluble Guanylate Cyclase Activators and Their Use
Patent: 9,938,260 →
Application: 15/509,895 →
Publication: US 2017/0305888
Heterocyclic Amides as Kinase Inhibitors
Application: 15/575,235 →
Publication: US 2018/0134665
METHODS FOR TREATING NEISSERIA GONORRHOEAE INFECTION WITH 2-({4-[(3,4-DIHYDRO-2H-PYRANO[2,3-c]PYRIDIN-6-YLMETHYL)AMINO]-1-PIPERIDINYL}METHYL)-1,2-DIHYDRO-3H,8H-2a,5,8a-TRIAZAACENAPHTHYLENE-3,8-DIONE
Application: 15/505,715 →
Publication: US 2017/0304301
Heterocyclic Amides Useful as Protein Modulators
Application: 15/730,664 →
Publication: US 2018/0105514
Carboxyesterase Biocatalysts
Application: 16/771,279 →
Publication: US 2021/0115417
Oxepinopyrazole Derivatives as Inhibitors of P13-Kinase Activity
Application: 16/604,605 →
Publication: US 2022/0324875
Compounds Useful in HIV Therapy
Application: 16/758,085 →
Publication: US 2020/0325147
Method for Treating Gonorrhea with (2R)-2-({4-[(3,4-Dihydro-2H-Pyrano[2,3-C]Pyridin-6-Ylmethyl)Amino]-1-Piperidinyl}Methyl)-1,2-Dihydro-3H,8H-2A,5,8A-Triazaacenaphthylene-3,8-Dione
Application: 16/918,084 →
Publication: US 2020/0330462
Novel Compounds for the Treatment of Parasitic Infections
Application: 16/963,539 →
Publication: US 2021/0047299
Chemical Compounds
Application: 16/572,917 →
Publication: US 2020/0071311
Novel Compounds
Application: 16/639,192 →
Publication: US 2021/0032268
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS PI4K INHIBITORS
Application: 16/961,704 →
Publication: US 2021/0387988
Methods for Purifying Antibodies
Application: 16/330,588 →
Publication: US 2021/0284686
Antibodies with Reduced Binding to Process Impurities
Application: 16/339,027 →
Publication: US 2019/0225708
Heterocyclic Amides as Kinase Inhibitors
Application: 16/299,254 →
Publication: US 2019/0201413
Ingenol Analogs, Pharmaceutical Compositions and Methods of Use Thereof
Application: 16/072,278 →
Publication: US 2019/0030029
Compounds
Application: 16/143,788 →
Publication: US 2019/0023715
Method of Producing a Recombinant Protein
Application: 16/098,890 →
Publication: US 2019/0177734
Antituberculosis Agent
Application: 16/087,161 →
Publication: US 2019/0091224
Chemical Compounds
Application: 16/073,355 →
Publication: US 2019/0040051
Biopharmaceutical Compositions Comprising Antibody Variants
Application: 17/056,816 →
Publication: US 2021/0115128
Biopharmaceutical Compositions and Related Methods
Application: 15/987,942 →
Publication: US 2018/0340023
Combination Treatment for Cancer with Anti-Bcma Binding Protein and Proteosome Inhibitor
Application: 16/646,836 →
Publication: US 2020/0270354
Heterocyclic Amides as Kinase Inhibitors
Application: 16/778,206 →
Publication: US 2020/0165205
Novel Processes for the Production of Oligonucleotides
Application: 16/833,724 →
Publication: US 2020/0277659
Immunogenic Composition, Use and Method of Treatment
Application: 16/499,001 →
Publication: US 2020/0046823
Novel Compounds
Application: 16/639,292 →
Publication: US 2020/0170997
Heterocyclic Amides as Kinase Inhibitors
Application: 16/061,497 →
Publication: US 2020/0270273
Biopharmaceutical Compositions Comprising Nucleic Acids Encoding Il-5 Binding Proteins
Application: 16/988,257 →
Publication: US 2021/0017269
Novel Tetrazole Compounds and Their Use in the Treatment of Tuberculosis
Application: 16/639,163 →
Publication: US 2020/0231555
C-Mannoside Compounds Useful for the Treatment of Urinary Tract Infections
Application: 17/063,947 →
Publication: US 2021/0017212
Novel Soluble Guanylate Cyclase Activators and Their Use
Application: 15/911,797 →
Publication: US 2018/0194756
Antibody Variants
Application: 15/749,210 →
Publication: US 2018/0222964
Fluticasone Furoate in the Treatment of Copd
Application: 17/205,466 →
Publication: US 2021/0205331
Novel Processes for the Production of Oligonucleotides
Application: 16/771,362 →
Publication: US 2024/0287566
Antibody Variants
Application: 15/930,225 →
Publication: US 2020/0339663
Modular Aseptic Production System
Application: 16/770,981 →
Publication: US 2021/0362898
Chemical Compounds
Application: 16/898,667 →
Publication: US 2020/0297710
Compounds
Application: 15/750,896 →
Publication: US 2018/0222911
Heterocyclic Amides as Kinase Inhibitors
Application: 17/156,478 →
Publication: US 2021/0253532
Compounds Useful in HIV Therapy
Application: 16/897,351 →
Publication: US 2020/0299309
Methods of Preparing Stable Liquid Therapeutic Protein Compositions
Application: 17/270,746 →
Publication: US 2021/0187107
Lid/Tray Package for an Inhalation Device
Patent: 679,586 →
Application: 29/426,021 →
Hydroxamic Acid Derivatives as Inhibitors of Hdac Enzymatic Activity
Patent: 7,973,181 →
Application: 11/919,048 →
Publication: US 2009/0298924
Buffer System for Protein Purification
Patent: 9,624,261 →
Application: 14/007,689 →
Publication: US 2014/0018525
Tray Package For an Inhalation Device
Patent: 754,533 →
Application: 29/485,918 →
Antigen Binding Proteins
Application: 14/208,684 →
Publication: US 2014/0286935
Hydroxamates as Inhibitors of Histone Deacetylase
Patent: 8,962,825 →
Application: 12/446,267 →
Publication: US 2010/0317678
Peptide Yy Analogs
Patent: 9,441,023 →
Application: 14/265,831 →
Publication: US 2014/0329742
Aggregate Particles
Patent: 9,763,965 →
Application: 14/394,132 →
Publication: US 2015/0083127
Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
Application: 14/371,956 →
Publication: US 2014/0356322
Heterocyclic Amides as Kinase Inhibitors
Patent: 9,556,152 →
Application: 14/763,183 →
Publication: US 2015/0353533
Anti-Lag-3 Binding Proteins
Application: 14/774,728 →
Publication: US 2016/0017037
Icos Binding Proteins
Patent: 9,771,424 →
Application: 15/006,560 →
Publication: US 2016/0215059
Fluticasone Furoate in the Treatment of Copd
Application: 15/313,769 →
Publication: US 2017/0189424
Novel Compounds
Patent: 9,868,724 →
Application: 15/314,107 →
Publication: US 2017/0101399
Compounds
Application: 15/327,706 →
Publication: US 2017/0204109
Novel Heteroaryl Substituted Compounds as Ror Gamma Inhibitors
Patent: 9,902,735 →
Application: 15/314,111 →
Publication: US 2017/0197978
C-Mannoside Compounds Useful for the Treatment of Urinary Tract Infections
Application: 17/371,419 →
Publication: US 2021/0395287
Compounds Useful in HIV Therapy
Application: 17/395,723 →
Publication: US 2022/0119417
Hepatitis B Immunisation Regimen and Compositions
Application: 17/436,183 →
Publication: US 2022/0339281
Non Peptidic Heterobivalent Molecules for Treating Inflammatory Diseases
Application: 17/412,070 →
Publication: US 2021/0379044
Process for the Purification of Recombinant Polypeptides
Application: 17/600,276 →
Publication: US 2022/0177517
MRGX2 Antagonists
Application: 17/492,978 →
Publication: US 2022/0112174
Novel Compounds
Application: 17/606,134 →
Publication: US 2022/0298197
Gepotidacin for Use in the Treatment of Bacterial Urinary Tract Infections
Application: 17/600,660 →
Publication: US 2022/0184071
Substituted Biphenyl or Phenylheteroaryl-Mannosides as Antagonists of Fimh
Application: 17/617,642 →
Publication: US 2022/0242900
IL-7 Binding Proteins and Their use in Medical Therapy
Application: 17/538,431 →
Publication: US 2022/0169717
Immunogenic Composition, Use and Method of Treatment
Application: 17/499,004 →
Publication: US 2022/0023409
5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7]naphthyridin-11(4bH)-one Compounds and Methods of Use
Application: 17/509,769 →
Publication: US 2022/0144834
2,3-Dihydroquinazolin Compounds as NAV1.8 Inhibitors
Application: 17/617,479 →
Publication: US 2023/0103791
Antigen Binding Proteins
Application: 17/530,849 →
Publication: US 2022/0089728
Combination for the Treatment of Infections Caused by Mycoplasma Genitalium
Application: 17/619,367 →
Publication: US 2022/0257615
Reducing Malaria Transmission
Application: 17/621,434 →
Publication: US 2023/0051209
Biopharmaceutical Compositions and Related Methods
Application: 17/633,115 →
Publication: US 2022/0289859
CR2 Binding Proteins and their use in Medical Therapy
Application: 17/639,096 →
Publication: US 2023/0032643
Method of Predicting Production Stability of Clonal Cell Lines
Application: 17/763,998 →
Publication: US 2022/0344000
Heterocyclic Amides Useful as Protein Modulators
Application: 17/663,749 →
Publication: US 2023/0071675
Treatment for Primary Amyloidosis with Anti-Bcma Binding Protein
Application: 17/846,950 →
Publication: US 2023/0019140
Method for Detecting Polysorbates
Application: 17/912,223 →
Publication: US 2023/0184750
Cathepsin Inhibitors for Preventing or Treating Viral Infections
Application: 17/913,870 →
Publication: US 2024/0066037
Antigen Binding Proteins
Application: 17/902,305 →
Publication: US 2023/0279106
Substituted Pyridines as DNMT1 Inhibitors
Application: 17/966,504 →
Publication: US 2023/0101987
Modular Aseptic Production System
Application: 17/896,538 →
Publication: US 2023/0050874
Combination Treatment for Cancer Involving Anti-Icos and Anti-PD1 Antibodies, Optionally Further Involving Anti-TIM3 Antibodies
Application: 17/911,937 →
Publication: US 2023/0140694
Combination Treatment for Cancer
Application: 17/911,816 →
Publication: US 2023/0131598
PI4KIIIBETA Inhibitors
Application: 17/941,838 →
Publication: US 2023/0124394
Display Screen with Graphical User Interface
Patent: 1,053,891 →
Application: 29/852,639 →
Chimeric Antigen Receptors Targeting Claudin-3 and Methods for Treating Cancer
Application: 17/950,667 →
Publication: US 2023/0192842
Crystalline Forms of Gepotidacin
Application: 17/997,293 →
Publication: US 2023/0167113
Carboxyesterase Biocatalysts
Application: 18/046,295 →
Publication: US 2023/0193227
Methods for Purifying Antibodies
Application: 17/978,791 →
Publication: US 2023/0046182
Antigen Binding Protein
Application: 18/006,924 →
Publication: US 2023/0279089
Antigen Binding Proteins
Application: 18/095,854 →
Publication: US 2023/0242642
Antigen Binding Proteins
Application: 18/098,792 →
Publication: US 2023/0295295
Interleukin 5 Binding Protein Dosage Regimen
Application: 18/258,588 →
Publication: US 2024/0043524
Chemical Compounds
Application: 18/330,569 →
Publication: US 2023/0416287
Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases
Application: 18/256,989 →
Publication: US 2025/0084112
Nitrogen Containing 2,3-Dihydroquinazolinone Compounds as Nav1.8 Inhibitors
Application: 18/256,982 →
Publication: US 2024/0083896
C-Mannoside Compounds Useful for the Treatment of Urinary Tract Infections
Application: 18/308,842 →
Publication: US 2023/0287028
Substituted Pyridines as DNMT1 Inhibitors
Application: 18/358,998 →
Publication: US 2024/0180933
Oral Solid Dose Formulations
Application: 18/262,938 →
Publication: US 2024/0366511
Antigen Binding Proteins and Combinations Thereof
Application: 18/552,477 →
Publication: US 2024/0166747
Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer
Application: 18/453,404 →
Publication: US 2024/0009307
IL-7 Binding Proteins and Their Use in Medical Therapy
Application: 18/460,944 →
Publication: US 2024/0025988
Combination Therapies for Treating Cancer
Application: 18/562,868 →
Publication: US 2025/0263495
Methods for Treating Infections Caused by Neisseria gonorrhoeae
Application: 18/509,964 →
Publication: US 2024/0108620
High-Throughput Assay for Cell Migration, Chemotaxis, and Function
Application: 18/833,282 →
Publication: US 2025/0116657
Pharmaceutical Compound
Application: 18/569,648 →
Publication: US 2024/0317774
Combination Therapies for Treating Cancer
Application: 18/697,515 →
Biopharmaceutical Compositions and Stable Isotope Labeling Peptide Mapping Method
Application: 18/291,272 →
Publication: US 2024/0369568
Triazole-Substituted Imidazo[1,2-a]Pyrimidines as Cgas Inhibitors
Application: 18/586,620 →
Publication: US 2024/0228503
Interleukin 5 Binding Protein Dosage Regimen for Use in Treating Polyangiitis, Hypereosinophilic Syndrome, Chronic Rhinosinusitis with Nasal Polyps (Crswnp), or Chronic Rhinosinusitis Without Nasal Polyps (Crssnp)
Application: 18/715,320 →
Publication: US 2025/0042985
Methods of Treating an Il-5 Mediated Disease by Administering an Il-5 Binding Protein
Application: 18/613,481 →
Publication: US 2024/0417456
Crispr/CAS9-Based Fusion Proteins for Modulating Gene Expression and Methods of Use
Application: 18/698,042 →
Publication: US 2025/0236854
Combination Therapy for Cancer
Application: 18/730,820 →
Compounds
Application: 18/646,178 →
Publication: US 2024/0300965
Pyrazine Compounds Useful in the Treatment of Parasitic Protozoal Infection
Application: 18/711,209 →
Publication: US 2025/0122167
Gepotidacin and Vancomycin for Use in the Treatment of an Infection Caused by Staphylococcus Saprophyticus
Application: 18/728,991 →
Publication: US 2025/0099535
Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
Application: 18/667,078 →
Publication: US 2024/0317729
Combination Therapy for Treating Hepatitis B Virus Infections
Application: 18/832,756 →
Publication: US 2025/0092401
Method of Treating Chronic Hepatitis B
Application: 18/851,303 →
Publication: US 2025/0215431
Antigen Binding Proteins
Application: 63/651,067 →
2,4-Dioxotetrahydropyrimidinyl Deratives as Degrons in Protacs
Application: 18/849,815 →
Publication: US 2025/0205344
PI4KIIIBETA Inhibitors
Application: 18/739,860 →
Publication: US 2024/0336618
Antigen Binding Proteins
Application: 63/662,557 →
Compounds
Application: 18/839,839 →
Publication: US 2025/0129084
Novel Processes for the Production of Polynucleotides Including Oligonucleotides
Application: 18/853,613 →
Publication: US 2025/0223620
IL-7 Binding Proteins and Their Use in Medical Therapy
Application: 18/823,000 →
Publication: US 2024/0425581
Cytotoxicity Targeting Chimeras
Application: 18/682,193 →
Publication: US 2025/0136722
Cytotoxicity Targeting Chimeras for CCR2-Expressing Cells
Application: 18/437,813 →
Publication: US 2024/0325392
Cytotoxicity Targeting Chimeras for C-C Chemokine Receptor 2-Expressing Cells
Application: 18/800,888 →
Publication: US 2025/0154288
Cytotoxicity Targeting Chimeras for CCR2-Expressing Cells
Application: 18/802,386 →
Publication: US 2025/0057958
Cytotoxicity Targeting Chimeras for CXCR3-Expressing Cells
Application: 18/802,915 →
Publication: US 2025/0051479
Cytotoxicity Targeting Chimeras for Prostate Specific Membrane Antigen-Expressing Cells
Application: 18/808,401 →
Publication: US 2025/0057827
Cytotoxicity Targeting Chimeras for Folate Receptor-Expressing Cells
Application: 18/808,367 →
Publication: US 2025/0049932
Cytotoxicity Targeting Chimeras for Fibroblast Activation Protein-Expressing Cells
Application: 18/812,114 →
Publication: US 2025/0064947
Nitrogen Containing Condensed 2,3-Dihydroquinazolinone Compounds as NAV1.8 Inhibitors
Application: 18/872,308 →
Compositions and Methods for Producing Smooth Muscle Cells
Application: 18/932,004 →
Publication: US 2025/0145959
Compositions and Methods for Producing Primordial Germ Cell-Like Cells
Application: 18/930,210 →
Publication: US 2025/0136933
5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended)
Application: 18/943,115 →
Publication: US 2025/0066361
Triazole-Substituted Imidazo[1,2-a]Pyrimidines as Cgas Inhibitors
Application: 18/966,276 →
Publication: US 2025/0092053
Anti-BCMA Antibody Drug Conjugate Combination Treatment for Cancer
Application: 18/985,239 →
Publication: US 2025/0122297
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Jun 6, 2022
From: CHARNLEY, ADAM K.; DONG, XIAOYANG; DODSON, JASON W.; RAMANJULU, JOSHI M.
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 060105/0468 →
Assignment of Assignor's Interest Jun 22, 2022
From: KHANDEKAR, SANJAY; MAYES, PATRICK; OPALINSKA, JOANNA
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 060279/0749 →
Assignment of Assignor's Interest Aug 26, 2022
From: SANMARTIN, FRANCESCO
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 060913/0224 →
Assignment of Assignor's Interest Sep 20, 2022
From: BARTON, NICHOLAS PAUL; BERTRAND, SOPHIE MARIE; DOWN, KENNETH; GRAY, MATTHEW
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 061488/0950 →
Assignment of Assignor's Interest Sep 20, 2022
From: BALLAS, MARC S.; ELLIS, CATHERINE E.; HIRSCHFELD, STEVEN
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 061158/0224 →
Assignment of Assignor's Interest Sep 20, 2022
From: BALLAS, MARC S.; ELLIS, CATHERINE E.; HIRSCHFELD, STEVEN
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 061158/0069 →
Assignment of Assignor's Interest Sep 23, 2022
From: BAVARI, SINA
To: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 061190/0931 →
Assignment of Assignor's Interest Sep 23, 2022
From: KANE, CHRISTOPHER; SOLOVEVA, VERONICA
To: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
Reel/Frame 061190/0682 →
Assignment of Assignor's Interest Sep 23, 2022
From: PEAT, ANDREW JAMES
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 061190/0820 →
Assignment of Assignor's Interest Oct 14, 2022
From: KISHORE, KAUSHAL; TALEKAR, MALA K.
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 061420/0943 →
Assignment of Assignor's Interest Oct 20, 2022
From: DEGENHARDT, YAN Y.; GUAN, JUN; HANCE, KENNETH WILLIAM; MORLEY, PETER JOSEPH
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 061482/0057 →
Assignment of Assignor's Interest Jan 12, 2023
From: HAMBLIN, PAUL ANDREW; LEWIS, ALAN PETER; WEBB, THOMAS MATTHEW
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 062362/0274 →
Assignment of Assignor's Interest Jan 19, 2023
From: HAMBLIN, PAUL ANDREW; LEWIS, ALAN PETER; WEBB, THOMAS MATTHEW
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 062420/0072 →
Assignment of Assignor's Interest Feb 27, 2023
From: CARNES, KATIE A.; SHEARER, JUSTIN W.
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 062815/0709 →
Assignment of Assignor's Interest Apr 19, 2023
From: COUCH, RICKY WAYNE; DAI, WENNING; DAVISON, SENTHIL; PENDRAK, ISRAIL
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 063363/0426 →
Assignment of Assignor's Interest May 2, 2023
From: BENOWITZ, ANDREW B.; KING, BRYAN WAYNE; ROMERIL, STUART PAUL; FOSBENNER, DAVID T
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 063504/0658 →
Assignment of Assignor's Interest Jun 28, 2023
From: CLARKSON, JANE E.; DIMECH, CAROLINE J.; HARRIS, CAROL A.; ZHANG, JIAN G.
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 064095/0818 →
Assignment of Assignor's Interest Jul 24, 2023
From: DONG, XIAOYANG; ELBAN, MARK ANDREW; GUANG, JIE; HO, MING-HSUN
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 064358/0182 →
Assignment of Assignor's Interest Aug 25, 2023
From: SPLETSTOSER, JARED TROY; MATTHEWS, JAY M.; PRICE, ALAN T.; GUANG, JIE
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 064702/0934 →
Assignment of Assignor's Interest Oct 29, 2024
From: GOKLEN, KENT E.; MOLEK, JESSICA RACHEL; DUMETZ, ANDRE; LEVY, NICHOLAS E.
To: GLAXOSMITHKLINE LLC
Reel/Frame 069050/0736 →
Assignment of Assignor's Interest Oct 29, 2024
From: GLAXOSMITHKLINE LLC
To: GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED
Reel/Frame 069050/0809 →
Assignment of Assignor's Interest Oct 29, 2024
From: GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 069050/0885 →
Assignment of Assignor's Interest Feb 19, 2025
From: BROWN, KRISTIN K.; DORR, BRENT M.; FUERST, DOUGLAS E.; HONICKER, KATHERINE JOYCE
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 070261/0646 →
Assignment of Assignor's Interest Feb 19, 2025
From: VOLADRI, RAMA
To: CODEXIS, INC.
Reel/Frame 070261/0869 →
Assignment of Assignor's Interest Feb 19, 2025
From: CODEXIS, LTD.
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Reel/Frame 070262/0036 →